TISSUE REGENIX GROUP PLC — Board/Management Information 2013

Feb 11, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6220X

Tissue Regenix Group PLC

11 February 2013

Director change

York, 11th February, 2013.

Tissue Regenix Group plc ('TRX') announced today that Mike Bretherton stepped down on 8 February 2013 as a non-executive director of Tissue Regenix Group plc.

Additionally, the trustees of the Company's employee benefit trust have today released a total of 250,414 ordinary shares of 0.5p each to Mike Bretherton under the terms of the Jointly Owned Equity agreements details of which are set out in note 17 of the Company's report and accounts to 31 January 2012.

John Samuel, Executive Chairman of Tissue Regenix Group plc commented: "I would like to thank Mike for his help and support at Tissue Regenix where he served as CFO after the reverse in 2010 and subsequently as a Non-Executive Director."

-ENDS-

For Further Information

Tissue Regenix Group plc:                                                             01904 435 176

Antony Odell

Peel Hunt LLP (Nominated Adviser):                                           020 7418 8900

James Steel

Vijay Barathan

Newgate Communications:

Alistair Kellie                                                                                    07557 651840

Andrew Adie                                                                                    07970 256512

Martin Greig                                                                                    07584 221513

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAGGUQAPUPWGCG